跳至主要内容
临床试验/RBR-7s99ksf
RBR-7s99ksf终止1 期

se of mesenchymal stromal cells for Steroid-refractory chronic Graft-versus-host Disease after hematopoietic stem cell transplantation

Hospital de Clínicas da Universidade Federal do Paraná - HCUFPR0 个研究点开始时间: 2022年8月5日最近更新:
适应症

试验速览

阶段
1 期
状态
终止
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
0 至 70Y(—)

入选标准

  • Age from zero to 70 years; patients (or their parents) who agree to participate in this study and who sign the informed consent form; patients after allogeneic hematopoietic stem cell transplantation;
  • classic chronic Graft-versus-host Disease or overlap syndrome, refractory to corticosteroid and calcineurin inhibitor treatment and/or interleukin 2 inhibitors. The refractory criteria will be worsening in three days, no improvement in seven days after the beginning of corticosteroid therapy, or no improvement after 21 days of the beginning of interleukin 2 inhibitors

排除标准

  • Patients who have any concomitant clinical condition that contraindicates the infusion of mesenchymal stem cells, in the physician's opinion; patient with respiratory failure requiring mechanical ventilation; patients with relapsed malignant disease

研究者

发起方
Hospital de Clínicas da Universidade Federal do Paraná - HCUFPR

相似试验

se of mesenchymal stromal cells for... | 临床试验